554 related articles for article (PubMed ID: 21270794)
1. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
3. Implementation of TPMT testing.
Lennard L
Br J Clin Pharmacol; 2014 Apr; 77(4):704-14. PubMed ID: 23962279
[TBL] [Abstract][Full Text] [Related]
4. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
Gisbert JP; González-Lama Y; Maté J
Gastroenterol Hepatol; 2006 Nov; 29(9):568-83. PubMed ID: 17129552
[TBL] [Abstract][Full Text] [Related]
6. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
Lennard L; Lilleyman JS
Ther Drug Monit; 1996 Aug; 18(4):328-34. PubMed ID: 8857546
[TBL] [Abstract][Full Text] [Related]
7. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
8. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
9. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Evans WE; Hon YY; Bomgaars L; Coutre S; Holdsworth M; Janco R; Kalwinsky D; Keller F; Khatib Z; Margolin J; Murray J; Quinn J; Ravindranath Y; Ritchey K; Roberts W; Rogers ZR; Schiff D; Steuber C; Tucci F; Kornegay N; Krynetski EY; Relling MV
J Clin Oncol; 2001 Apr; 19(8):2293-301. PubMed ID: 11304783
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions.
Lennard L
Ther Drug Monit; 1998 Oct; 20(5):527-31. PubMed ID: 9780130
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the pharmacogenomics of thiopurine methyltransferase.
Coulthard SA; Hall AG
Pharmacogenomics J; 2001; 1(4):254-61. PubMed ID: 11908768
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Hindorf U; Lindqvist M; Peterson C; Söderkvist P; Ström M; Hjortswang H; Pousette A; Almer S
Gut; 2006 Oct; 55(10):1423-31. PubMed ID: 16543290
[TBL] [Abstract][Full Text] [Related]
13. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.
Kurzawski M; Dziewanowski K; Gawrońska-Szklarz B; Domański L; Droździk M
Ther Drug Monit; 2005 Aug; 27(4):435-41. PubMed ID: 16044099
[TBL] [Abstract][Full Text] [Related]
14. Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong VW; Shipkova M; von Ahsen N; Oellerich M
Ther Drug Monit; 2004 Apr; 26(2):220-6. PubMed ID: 15228169
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
Lennard L; Welch JC; Lilleyman JS
Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.
Yates CR; Krynetski EY; Loennechen T; Fessing MY; Tai HL; Pui CH; Relling MV; Evans WE
Ann Intern Med; 1997 Apr; 126(8):608-14. PubMed ID: 9103127
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of TPMT polymorphism in Indian patients requiring immunomodulator therapy and its clinical significance.
Davavala SK; Desai DC; Abraham P; Ashavaid T; Joshi A; Gupta T
Indian J Gastroenterol; 2014 Jan; 33(1):41-5. PubMed ID: 23996738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
